Immutep Collaborates with Dr. Reddy’s to Develop & Commercialize Eftilagimod Alfa

Shots: Immutep and Dr. Reddy’s Laboratories have entered into a strategic collaboration and exclusive licensing agreement to develop and commercialize Eftilagimod Alfa (efti) across all countries outside North America, Europe, Japan, and Greater China As per the deal, Immutep will receive a $20M (~AUD 30.2M) upfront payment from Dr. Reddy’s, plus potential milestone payments of up…

ByDipanshu DixitDecember 9, 2025

TOP 20

Top 20 R&D Spending Biopharma Companies of 2025

Shots: Research and Development (R&D) serves as the driving force behind groundbreaking therapeutic innovations, laying the foundation for advancements that transform patient health and overall well-being The global Top 20 pharmaceutical leaders spent ~$180B in 2024, with Merck & Co. contributing the most with a whopping $17.93B, followed by Johnson & Johnson ($17.23B) and Roche…

ByPrince GiriAugust 21, 2025

NEWS

Philochem and RayzeBio Enter Into a Development and Commercialization Deal of ~$1.35B

Shots: Philochem and RayzeBio (BMS) entered into a development and commercialization agreement under which Philochem granted RayzeBio exclusive worldwide rights to develop, manufacture, and commercialize its radiopharmaceutical agent OncoACP3 for prostate cancer Under the agreement, Philochem will receive $350M up front and is eligible for up to $1B in development, regulatory, and commercial milestones, plus…

ByPrince GiriJune 11, 2025

NEWS

Alnylam Pharmaceuticals and Sanofi Report the US FDA’s Approval of Qfitlia (Fitusiran) to Treat Hemophilia A or B

Shots: The US FDA has approved Qfitlia to treat routine prophylaxis and prevent or reduce the frequency of bleeding episodes in pts. (age≥ 12yrs.) with hemophilia A or B, with or without factor VIII or IX inhibitors. Regulatory submissions have been completed in China & Brazil Qfitlia published clinical data in the NEJM in 2017, showing…

ByRidhi RastogiApril 1, 2025

VIEWPOINTS

Inherited Retinal Disease Management: Brian Strem from Kiora Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots

Shots: Recently, Kiora Pharmaceuticals received an upfront payment of $16M after inking the partnership agreement with Théa Open Innovation to develop and commercialize KIO-301 and is eligible to receive up to $285M KIO-301 belongs to a new-generation drug called molecular switches that offer a path around damaged receptors rather than looking to repair gene mutation …

BySaurabh ChaubeyJuly 15, 2024

VIEWPOINTS

CSAP Management: Uwe P Tigör from Auxilius Pharma in Conversation with PharmaShots

Shots: Chronic Stable Angina Pectoris (CSAP) affects over 11M patients in the US. Often considered as the first manifestation of an underlying coronary disease, there is a dearth of new-age innovative anti-anginal drugs Today at PharmaShots we have Uwe P Tigör, Co-founder and Chief Medical Officer at Auxilius Pharma, shedding light on the positive results…

BySaurabh ChaubeyJune 5, 2024

TOP 20

Top 20 Biopharma Deal Terminations of 2023 Based on Total Deal Value

Shots: Sticking to M&A and licensing agreements can be really challenging, especially when dealing with stringent antitrust laws and evolving regulatory challenges. In such adverse scenarios, the rational and right step seems to be nullifying the existing deals. In 2023, the termination of the deal between Janssen and Arrowhead remained the talk of the town…

ByPrince GiriApril 18, 2024

VIEWPOINTS

Fund Secured: MediWounds’ CEO Ofer Gonen in Conversation with PharmaShots

Shots: Ofer Gonen, CEO at MediWound, in conversation with PharmaShots, sheds light on recent funding from the US Department of Defence to further develop NexoBrid for the US Army NexoBrid an FDA-approved enzymatic therapy to treat severe burns is jointly developed by Vericel and received US FDA approval in Dec’22 MediWound secured an additional $6.7M…

BySaurabh ChaubeyApril 4, 2024

VIEWPOINTS

PharmaShots Interview: Adagio Therapeutics’ Tillman Gerngross Shares Insight on the Development of Antibodies to Prevent COVID-19

In an interview with PharmaShots, Tillman Gerngross, Ph.D., Co-Founder, and CEO of Adagio Therapeutics shed light on the pre-clinical data of ADG2 and how it works on SARS-CoV-2. Shots: ADG2 showed broad and potent neutralizing activity against SARS-CoV and two SARS-related coronaviruses currently known to be circulating in bat populations (WIV-1 and SHC014) The company expects ADG20 to enter clinical studies…

BySenior EditorMarch 1, 2021

THOUGHTSPOT

The New Normal and Covid-19 Vaccine Development

Since the virus outbreak in China, all eyes are on the most awaited Covid-19 vaccine offering a glimmer of hope. Abide by social distancing, wearing a mask, and frequent hand washing - until we have a vaccine. This new mantra amidst all misery has created hope in the hearts of many. We have to accept…

BySenior EditorAugust 5, 2020

Immutep Collaborates with Dr. Reddy’s to Develop & Commercialize Eftilagimod Alfa

Top 20 R&D Spending Biopharma Companies of 2025

Philochem and RayzeBio Enter Into a Development and Commercialization Deal of ~$1.35B

Alnylam Pharmaceuticals and Sanofi Report the US FDA’s Approval of Qfitlia (Fitusiran) to Treat Hemophilia A or B

Inherited Retinal Disease Management: Brian Strem from Kiora Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots

CSAP Management: Uwe P Tigör from Auxilius Pharma in Conversation with PharmaShots

Top 20 Biopharma Deal Terminations of 2023 Based on Total Deal Value

Fund Secured: MediWounds’ CEO Ofer Gonen in Conversation with PharmaShots

PharmaShots Interview: Adagio Therapeutics’ Tillman Gerngross Shares Insight on the Development of Antibodies to Prevent COVID-19

The New Normal and Covid-19 Vaccine Development

Contact US

FOLLOW US